+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Immunotherapy Market - Global Forecast 2026-2032- Product Image
Cancer Immunotherapy Market - Global Forecast 2026-2032- Product Image
New

Cancer Immunotherapy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010622
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer immunotherapy market is redefining oncology by offering transformative approaches for both clinicians and stakeholders. As novel scientific breakthroughs reach the clinic, executive decision-makers must navigate ongoing shifts spanning research, regulation, technology, and global commercialization to compete and innovate successfully in this high-impact sector.

Market Snapshot: Cancer Immunotherapy Market Size and Growth

The cancer immunotherapy market continues on an upward trajectory, expanding from USD 81.74 billion in 2025 to USD 86.14 billion in 2026. Projected to grow at a 5.73% CAGR, the market is expected to reach USD 120.75 billion by 2032. This consistent expansion is powered by the rapid clinical integration of immuno-oncology therapies, ongoing innovation, and increasing demand for personalized treatments within cancer care. Commercial interest remains strong across major global markets, as stakeholders prioritize solutions that improve both patient outcomes and operational efficiency.

Cancer Immunotherapy Market: Scope & Segmentation

  • Therapy Modalities: Covers cancer vaccines, CAR-T therapies, checkpoint inhibitors (such as PD-1, PD-L1, CTLA-4), adoptive cell transfers, and oncolytic virus-based treatments.
  • Mechanisms of Action: Addresses checkpoint inhibition, cytokine-based therapy, vaccine-driven immunity, cell-based interventions, and oncolytic viral approaches—each differentiated by efficacy profile, safety, and delivery method.
  • Lines of Therapy: Includes first-line, second-line, and subsequent uses, impacting trial structuring, competitive positioning, and time-to-market considerations across breakthrough and established therapies.
  • Routes of Administration: Examines intravenous, subcutaneous, and intratumoral deliveries, directly shaping patient experience and influencing healthcare provider adoption and site-of-care logistics.
  • Indications: Encompasses hematologic malignancies (e.g., leukemia, lymphoma, myeloma) and solid tumors (such as breast, lung, colorectal cancers, and melanoma), reflecting wide-ranging clinical utility.
  • End-User Settings: Research institutes, hospitals, and specialty clinics constitute primary settings, each requiring tailored distribution, education, and support strategies.
  • Geographic Regions: Analyzes dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with a focus on regulatory diversity, patient access, and regionally adapted commercialization tactics.
  • Technological Platforms: Assesses the impact of emerging technology, including cell and gene engineering, digital batch traceability, and modular manufacturing, on workflow optimization and supply reliability.

Key Takeaways for Decision-Makers

  • Immunotherapy is now established as a primary option in cancer care, influencing clinical design and expanding choices for diverse patient populations.
  • Progress in translational science backed by real-world evidence is compressing the time from discovery to patient delivery, prompting the need for agile and scalable operational models.
  • Effective use of combination and sequencing therapies, informed by robust biomarker data, is guiding best practices to optimize safety and duration of response.
  • Integration of clinical and regulatory strategies is critical as evidence requirements evolve and payers demand rigorous proof of therapeutic value prior to widespread market entry.
  • Commercial success increasingly relies on the generation of high-quality evidence, enhanced negotiation with payers, and systems to demonstrate sustained benefit.
  • Strategic collaborations and detailed region-specific approaches help to mitigate challenges arising from divergent approval processes and infrastructure disparities across markets.

Cancer Immunotherapy Market: Tariff Impact and Supply Chain Considerations

Newly introduced tariff measures in the United States are altering global supply chains and influencing manufacturing site selection. These pressures are compelling companies to reevaluate supplier relationships, regional investment choices, and risk management practices. With heightened input costs for biologic raw materials and essential components, greater supply chain agility and meticulous production scheduling have become priorities. Collaboration between procurement, clinical, and commercial functions is required to maintain patient access and minimize cost exposure, while geographical focus shifts towards markets with streamlined regulation and favorable pricing frameworks.

Methodology & Data Sources

This report combines expert interviews, regulatory analysis, and comprehensive supply chain reviews within a mixed-methods framework. Quantitative findings are validated with qualitative insights to provide an integrated perspective on both overarching trends and market-specific disruptions.

Why This Report Matters

  • Delivers targeted intelligence for designing flexible manufacturing strategies and market launches tailored to specific regional landscapes.
  • Supports fact-based decisions in R&D allocation, development prioritization, and adaptation of commercial models within an evolving policy environment.
  • Empowers leaders to anticipate regulatory shifts and optimize portfolio advancement under changing external pressures.

Conclusion

A harmonized strategy combining scientific advancement, robust operations, and focused evidence generation is fundamental for capturing opportunity in cancer immunotherapy. Ongoing intelligence gathering supports long-term competitiveness while strengthening patient and stakeholder value globally.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cancer Immunotherapy Market, by Therapy Type
8.1. Cancer Vaccines
8.2. CAR-T Therapy
8.3. CTLA-4 Inhibitors
8.4. Oncolytic Virus Therapy
8.5. PD-1 Inhibitors
8.6. PD-L1 Inhibitors
9. Cancer Immunotherapy Market, by Mechanism Of Action
9.1. Adoptive Cell Transfer
9.2. Checkpoint Inhibitors
9.3. Cytokine Therapy
9.4. Oncolytic Virus Therapy
9.5. Vaccine Therapy
10. Cancer Immunotherapy Market, by Line Of Therapy
10.1. First Line
10.2. Fourth Line And Beyond
10.3. Second Line
10.4. Third Line
11. Cancer Immunotherapy Market, by Route Of Administration
11.1. Intratumoral
11.2. Intravenous
11.3. Subcutaneous
12. Cancer Immunotherapy Market, by Indication
12.1. Hematologic Malignancies
12.1.1. Leukemia
12.1.2. Lymphoma
12.1.3. Multiple Myeloma
12.2. Solid Tumors
12.2.1. Breast Cancer
12.2.2. Colorectal Cancer
12.2.3. Lung Cancer
12.2.4. Melanoma
13. Cancer Immunotherapy Market, by End User
13.1. Hospitals
13.2. Research Institutes
13.3. Specialty Clinics
14. Cancer Immunotherapy Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Cancer Immunotherapy Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Cancer Immunotherapy Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Cancer Immunotherapy Market
18. China Cancer Immunotherapy Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Amgen Inc.
19.6. AstraZeneca PLC
19.7. BeiGene, Ltd.
19.8. bluebird bio, Inc.
19.9. Bristol-Myers Squibb Company
19.10. Cellectis S.A.
19.11. Daiichi Sankyo Company, Limited
19.12. Fate Therapeutics, Inc.
19.13. Gilead Sciences, Inc.
19.14. GlaxoSmithKline plc
19.15. Iovance Biotherapeutics, Inc.
19.16. Johnson & Johnson
19.17. Kite Pharma
19.18. Merck KGaA
19.19. Novartis AG
19.20. Pfizer Inc.
19.21. Regeneron Pharmaceuticals, Inc.
19.22. Roche Holding AG
19.23. Sanofi
19.24. Seagen Inc.
List of Figures
FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 139. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 141. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 144. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 157. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 158. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 159. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 162. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 163. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 176. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 177. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 178. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 180. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 181. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 182. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 185. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 186. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 187. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 189. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 190. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 191. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 203. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 204. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 205. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 206. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 207. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 208. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 209. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 212. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 213. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 214. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 216. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 217. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 218. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 221. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 222. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 223. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 225. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 226. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 227. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 239. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 240. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 241. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 242. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 244. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 245. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 246. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Cancer Immunotherapy market report include:
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Cellectis S.A.
  • Daiichi Sankyo Company, Limited
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Kite Pharma
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Seagen Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 86.14 Billion
Forecasted Market Value ( USD ) by 2032 $ 120.75 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Immunotherapy Drugs Market - Global Forecast 2025-2032 - Product Image

Immunotherapy Drugs Market - Global Forecast 2025-2032

  • Report
  • 180 Pages
  • Global
From
Cancer Immunotherapy Drugs Market - Global Forecast 2025-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2025-2032

  • Report
  • 197 Pages
  • Global
From
Oncolytic Virus Immunotherapy Market - Global Strategic Business Report - Product Image

Oncolytic Virus Immunotherapy Market - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Cancer Immunotherapy Market Report 2025 - Product Image

Cancer Immunotherapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.